Brexucabtagene Autoleucel Designated as Orphan Drug for MCL and B-ALL Gilead Sciences has received orphan drug designation for Brexucabtagene Autoleucel, aiding patients suffering from MCL and B-ALL.

Brexucabtagene Autoleucel Designated as Orphan Drug for MCL and B-ALL #Japan #Tokyo #Gilead_Sciences #Kite_Pharma #Brexucabtagene

Wat een fantastische bedrijven hebben we toch in @haarlemmermeer! Gisteravond spatte de #ondernemerszin er van af bij het MeerBusiness Gala. Hier onze winnaars: #Ploeg_Kozijnen, #Kite_Pharma en #Van_Leeuwen_Sloopwerken

Gilead Sciences Initiates Program to Address Regional Disparities in CAR T Cell Therapy Access Gilead Sciences has adopted proposals from three organizations to improve access to CAR T cell therapy, addressing regional healthcare disparities.

Gilead Sciences Initiates Program to Address Regional Disparities in CAR T Cell Therapy Access #Japan #Tokyo #CAR_T_Therapy #Gilead_Sciences #Kite_Pharma